Frontlight ResearchEarly access
CompletedPhase 2
Ketamine-enhanced Prolonged Exposure Therapy in PTSD
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 73 people enrolled
- Started
- 9 Mar 2021
- Ended
- 7 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ketamine
- Midazolam
- Record updated
- 11 August 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- male or female Veterans between the ages of 18 and 75 years
- diagnosis of PTSD
- ability to provide written informed consent
Who cannot take part
- history of moderate/severe head injury
- history of psychosis
- severe substance and/or alcohol use disorder in the last 6 months
- females who are currently pregnant or breastfeeding
- current high risk for suicide
- current episode of mania/hypomania
Where in United States
- Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United States
About the trial
What the trial wants to find out
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.
The 2 groups in the trial
- Ketamine and prolonged exposure (PE)Treatment being tested
Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Treatment: Ketamine
- Midazolam and prolonged exposure (PE)Placebo, for comparison
Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Treatment: Midazolam
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Repeated Ketamine Treatment to Accelerate Efficacy of Prolonged Exposure in PTSD
- Record updated
- 11 August 2026